Brensocatib Mechanism of Action: First DPP-1 Inhibitor for Non Cystic Fibrosis Bronchiectasis

Brensocatib (Brinsupri) made history as the first FDA-approved treatment for non–cystic fibrosis bronchiectasis (NCFB), and the first ever DPP-1 inhibitor approved for a neutrophil-mediated disease. In this video, we break down: • What non-CF bronchiectasis is and why neutrophils drive the damage • How brensocatib works at the molecular level to block destructive proteases • Key findings from the ASPEN trial, the largest bronchiectasis study to date • Why experts call this approval a landmark in respiratory medicine Whether you’re a pharmacology student looking to understand the mechanism of action or a healthcare professional curious about the clinical impact, this video brings you a clear explanation of how brensocatib changes the game. Disclaimer: This YouTube channel is not intended to provide diagnosis, treatment, or medical advice. The content provided in this video is for informational purposes only. This should not be considered as a substitute for healthcare professional advice. Please consult a physician or other healthcare professional regarding any medical or health-related diagnosis or treatment options. The statements about specific products are not to diagnose, treat, cure, or prevent disease. References: 1. https://www.ajmc.com/view/brensocatib... 2. Chalmers JD, Burgel PR, Daley CL, et al. Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. N Engl J Med. 2025;392(16):1569-1581. doi:10.1056/NEJMoa2411664 3. A study to assess the efficacy, safety, and tolerability of brensocatib in participants with non-cystic fibrosis bronchiectasis (ASPEN). ClinicalTrials.gov. Updated November 12, 2024. Accessed September 5, 2025. https://clinicaltrials.gov/study/NCT0... 4. Bonavitacola J, Steinzor P, Chalmers J. ASPEN trial shows efficacy of brensocatib in different dosages. AJMC. May 31, 2025. Accessed September 5, 2025. https://www.ajmc.com/view/aspen-trial... 5. Brensocatib show consistent efficacy and safety across three prespecified subgroups in new data from landmark ASPEN study. News release. Insmed. May 21, 2025. Accessed September 5, 2025. https://investor.insmed.com/2025-05-2... #Pharmacology #Brensocatib #Bronchiectasis #RespiratoryMedicine #PharmaNews #ClinicalTrials #DrugMechanism #MedicalEducation #Neutrophils #FDAApproval #PharmacologyMadeSimple #PharmacyEducation